Daiichi Sankyo Archives - Page 7 of 7 -

Daiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become

Daiichi gets speedy FDA review for rare cancer drug

https://pharmaphorum.com/news/daiichi-speedy-fda-review-rare-cancer-drug/

Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for

Daiichi Sankyo takes option on diabetes stem cell start-up

https://pharmaphorum.com/news/daiichi-sankyo-takes-option-on-diabetes-stem-cell-start-up/

The FDA has approved Astellas’ Xospata for certain patients with acute myeloid leukaemia – the company’s first drug

Astellas scores first US blood cancer approval with Xospata

https://pharmaphorum.com/news/astellas-scores-first-us-blood-cancer-approval-with-xospata/

A leukaemia drug has been granted ‘breakthrough therapy’ status by the US drug regulator. Daiichi Sankyo announced that

FDA grants leukaemia drug ‘breakthrough’ status

https://pharmaphorum.com/market-access-2/fda-grants-leukaemia-drug-breakthrough-status/

Merck & Co has dominated proceedings at the American Society of Clinical Oncology (ASCO), with a steady flow

ASCO 2018 – Monday 4th June: BMS tries different tack as Merck & Co locks out lung cancer I/O

https://pharmaphorum.com/event-coverage/asco-2018-bms-merck-co-locks-out-lung-cancer-i-o/

Trading in shares of Daiichi Sankyo was suspended yesterday.

AZ tried to buy Daiichi Sankyo last year – report

https://pharmaphorum.com/news/az-tried-buy-daiichi-sankyo-last-year-report/

Label gives guidance in use when restoring normal heart rhythm

Daiichi Sankyo anticoagulant gains EU label boost

https://pharmaphorum.com/news/daiichi-sankyo-noac-get-eu-label-boost/

Japanese R&D investment could follow EMA out of UK – experts.

Nissan stays in UK – but will Japanese pharma?

https://pharmaphorum.com/news/nissan-stays-uk-will-japanese-pharma/

Daiichi Sankyo